A Prospective Randomized Trial Comparing Hydrus and iStent Microinvasive Glaucoma Surgery Implants for Standalone Treatment of Open-Angle Glaucoma

Two-year outcomes of the MINIject drainage system for uncontrolled glaucoma from the STAR-I first-in-human trial

“…18 Trabecular bypass stents can also serve as comparators although they target the conventional outflow pathway. The recent COMPARE trial 19 compared stand-alone 12-month outcomes of two iStent Trabecular Micro Bypass devices (Glaukos, San Clemente, CA, USA) with one Hydrus Microstent (Ivantis, Irvine, CA, USA). At baseline, mean medicated IOP was 19.0 ±3.9 (Hydrus, n=77) and 19.1±3.6 mmHg (2-iStent, n=77) on a mean of 2.5±0.7 (Hydrus) and 2.7±0.8 (2-iStent) medications.…”

Reply

“…We appreciate the opportunity afforded by Dr Khouri's inquiry to highlight them again. 1 we wish to offer the following feedback. We appreciate the authors' review of the Laser Intervention in Early Stages of Age-Related Macular Degeneration (LEAD) study, 2 as well as their assessment of the role of nascent geographic atrophy in AMD.…”

Re: Ahmed et al.: A prospective randomized trial comparing Hydrus and iStent micro-invasive glaucoma surgery implants for standalone treatment of open-angle glaucoma: The COMPARE Study (Ophthalmology. 2020;127:52–61)

“…In the UK, our genetic diagnostic service applies rigorous variant assessment in accordance with the American College of Medical Genetics and Genomics (ACMG) 1 and The Association for Clinical Genomic Science (ACGS) guidance (www.acgs.uk.com/quality/ best-practice-guidelines/). The overall reported diagnostic yield of 68 of 277 samples in our study links partly to inclusion of conditions such as microphthalmia and coloboma and anterior segment developmental anomalies, for which our study indicates incomplete knowledge regarding the genetic etiology, and also to rigor in variant assessment and caution against overinterpretation of findings.…”

“…By sharing data within our Genomics England Clinical interpretation partnerships and with external collaborators outside the UK, over time this open approach is designed to achieve consensus on which new genes have sufficient evidence for diagnostic testing. JANE C. SOWDEN, PHD 1 AARA PATEL, MSC, PHD 1 ANNEGRET DAHLMANN-NOOR, MD, PHD 2 THOMAS CULLUP, BSC, FRCPATH 3 LUCY JENKINS, FRCPATH The study originally included a 12-month washout, which would enable a direct comparison of intraocular pressure (IOP) not confounded by medications. However, this critical washout requirement was eliminated midstream during the study, with a protocol modification, thus, fundamentally altering end points.…”